Recent Big 4 diabetes articles

[Department of Error] Department of Error
...type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073–84—In this Article (March 29), the fifth line from the bottom of the panel (p 1075) should have read: “≤5·5 mmol/L: no further titration”. The second sentence of the footnote to table 2 (p 1079) should have read: “Fasting blood gluc...
The Lancet - 10:40 (1 hour ago)


[Correspondence] Intensive insulin therapy in patients with type 2 diabetes – Authors' reply
...latent autoimmune diabetes in adults in our population. Although there is no formal consensus regarding diagnostic criteria, the disorder is generally defined as GAD antibody positivity in adult diabetic patients who do not initially (for at least 6 months) require insulin. Usually patients with latent autoimmune diabetes have a low body-mass in...
The Lancet - 10:40 (1 hour ago)


[Correspondence] Intensive insulin therapy in patients with type 2 diabetes
...type 2 diabetes (May 24, p 1573) is an exciting prospect.
The Lancet - 10:40 (1 hour ago)


[Correspondence] Intensive insulin therapy in patients with type 2 diabetes
Jianping Weng and colleagues are to be commended for building a concept that could change clinical practice. However, their conclusions need some clarification.
The Lancet - 10:40 (1 hour ago)


CORRESPONDENCE: Widespread Amyloid Deposition in Transplanted Human Pancreatic Islets
...type 1 diabetes mellitus, diagnosed at 16 years of age, in ...
New England Journal of Medicine - 27 Aug 2008 (2 days ago)



CARING FOR THE CRITICALLY ILL PATIENT: Benefits and Risks of Tight Glucose Control in Critically Ill Adults: A Meta-analysis
...The American Diabetes Association and Surviving Sepsis Campaign recommend tight glucose control in critically ill patients based largely on 1 trial that shows decreased mortality in a surgical intensive care unit. Because similar studies report conflicting results and tight glucose control can cause dangerous hypoglycemia, the data underlying th...
JAMA current issue - 26 Aug 2008 (3 days ago)


[RESEARCH] Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study
...type 1 diabetes. Design Prospective cohort study. Setting Diabetes Complications Assessment Service at the Children’s Hospital at Westmead, Sydney, Australia. Participants 1869 patients with type 1 diabetes (54% female) screened for retinopathy with baseline median age 13.4 (interquartile range 12.0-15.2) years, duration 4.9 (3.1-7.0) years, and...
BMJ current issue - 26 Aug 2008 (3 days ago)


[EDITORIALS] Complications of type 1 diabetes in adolescents
BMJ current issue - 26 Aug 2008 (3 days ago)


[NEWS] Diabetes care needs to focus more on ethnic inequalities, say experts
BMJ current issue - 22 Aug 2008 16:46

[PRACTICE] Should we prescribe diuretics for patients with prediabetes and hypertension?
BMJ current issue - 21 Aug 2008 14:44


LETTERS: Insulin Therapy and Lipid Overload in Type 2 Diabetes--Reply
JAMA current issue - 19 Aug 2008 21:44

LETTERS: Insulin Therapy and Lipid Overload in Type 2 Diabetes
JAMA current issue - 19 Aug 2008 21:44

LETTERS: Pioglitazone vs Glimepiride in the PERISCOPE Trial
JAMA current issue - 19 Aug 2008 21:44


EDITORIAL: Environmental Arsenic Exposure and Diabetes
JAMA current issue - 19 Aug 2008 21:44

LETTERS: Pioglitazone vs Glimepiride in the PERISCOPE Trial--Reply
JAMA current issue - 19 Aug 2008 21:44



LETTERS: Pioglitazone vs Glimepiride in the PERISCOPE Trial
JAMA current issue - 19 Aug 2008 21:44


LETTERS: Insulin Therapy and Lipid Overload in Type 2 Diabetes
JAMA current issue - 19 Aug 2008 21:44


PRELIMINARY COMMUNICATION: Arsenic Exposure and Prevalence of Type 2 Diabetes in US Adults
...related to diabetes development, but the effect of exposure to low to moderate levels of inorganic arsenic on diabetes risk is unknown. In contrast, arsenobetaine, an organic arsenic compound derived from seafood intake, is considered nontoxic. Objective To investigate the association of arsenic exposure, as measured in urine, with the prevalen...
JAMA current issue - 19 Aug 2008 21:44

[Seminar] Acute myocardial infarction
...epidemic of diabetes and obesity in the developed world and the transition from infectious diseases to cardiovascular disease in the developing world will place an increasing demand on health-care infrastructures required to deliver time-dependent and resource-intensive care. This Seminar discusses the underlying pathophysiology, evolving perspe...
The Lancet - 15 Aug 2008 11:00

[Articles] Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
...or with diabetes with end-organ damage.
The Lancet - 15 Aug 2008 11:00

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 25-2008 -- A 43-Year-Old Man with Fatigue and Lesions in the Pituitary and Cerebellum
...Diabetes insipidus, hypogonadism, and hypothyroidism had developed beginning 9 years earlier, and lesions had been detected in the region of the pituitary stalk and in the cerebellum. He was treated with glucocorticoids for suspected neurosarcoidosis, but fatigue, ataxia, and neurologic symptoms worsened. Computed tomography of the chest and abd...
New England Journal of Medicine - 13 Aug 2008 22:25

[CORRECTIONS] Evidence shows higher long term risks from gestational diabetes
BMJ current issue - 6 Aug 2008 17:36

Basal insulin glargine vs prandial insulin lispro in type 2 diabetes
Reinhard Bretzel and colleagues (March 29, p 1073) compared once-daily insulin glargine with thrice-daily prandial insulin lispro as add-on therapy to continued oral hypoglycaemic agents. Although glycosylated haemoglobin did not differ between regimens, the overall incidence of hypoglycaemic events was four times higher with insulin lispro than wi...
The Lancet - 1 Aug 2008 11:15

Basal insulin glargine vs prandial insulin lispro in type 2 diabetes – Authors' reply
Sabine Arnolds and Klaus Rave state that the higher hypoglycaemic rate in the lispro group than in the glargine group was potentiated by the presence of glimepiride. However, the relative frequencies of hypoglycaemic events by hour of day showed a similar distribution profile, with peaks at 2 pm for lispro and 3 pm for glargine. A further explanati...
The Lancet - 1 Aug 2008 11:15